Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of THR-687 in Diabetic Macular Edema
NCT03666923Phase 1Completed
- Sponsor
- Oxurion
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of THR-687 in diabetic macular edema (DME) (3 arms), sponsored by Oxurion. Primary endpoint: Incidence of dose-limiting toxicities at Day 14. Started Sep 2018; status: completed.
02
Drugs
THR-687
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03666923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666923.